alpha-aminopyridine has been researched along with Dysplastic Nevus Syndrome, Hereditary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blackham, A; Box, J; Demberger, L; Federowicz, B; Friedland, JC; Ginn, S; Horton, M; Knoerzer, D; McIntosh, A; Nair, S; Shapiro, M; Sheikh, H; Stuhlmiller, TJ; Wolfe, Z | 1 |
| Aptullahoglu, E; Esfandiari, A; Ho, YH; Lovat, P; Lunec, J; Mahdi, AK; Wang, N; Wu, CE | 1 |
2 other study(ies) available for alpha-aminopyridine and Dysplastic Nevus Syndrome, Hereditary
| Article | Year |
|---|---|
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma.
Topics: Aminopyridines; Cell Line, Tumor; Humans; MAP Kinase Signaling System; Melanoma; Melanoma, Cutaneous Malignant; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrroles; Skin Neoplasms | 2022 |
Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
Topics: Aminopyridines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dipeptides; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Melanoma, Cutaneous Malignant; Mutagenesis, Site-Directed; para-Aminobenzoates; Phosphorylation; Piperazines; Protein Binding; Protein Phosphatase 2C; Protein Stability; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Skin Neoplasms; Tumor Suppressor Protein p53 | 2018 |